Establishment and characterization of a new HPV-negative squamous cell carcinoma cell line (Yumoto) from the human uterine cervix

Gynecologic Oncology

Volumn 70, Issue 3, 1998, Pages 339-347

  Mitsuhashi, Akira ^a   Tanaka, Hirokazu ^a   Tanaka, Naotake ^a   Sugita, Michio ^a   Shirasawa, Hirosi ^a   Tokita, Hisashi ^b   Eda, Hiroyuki ^c   Sekiya, Souei ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c Division of Oncology and Immunology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELL ULTRASTRUCTURE; DNA DETERMINATION; DNA SEQUENCE; ELECTRON MICROSCOPY; FEMALE; GENE DELETION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

EID: 0032169783     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5072     Document Type: Article

References (36)

1. Munoz N, Bosch X, Kaldor J M. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer. 57:1988;1-5.
2. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49:1989;4677-4681.
3. zur Hausen H. Viruses in human cancers. Science. 254:1991;1167-1173.
4. Myers, G, Bernard, H, U, Delius, H, Baker, C, Icenogel, J, Halpern, A, Wheeler, C, A complication and analysis of nucleic acid and amino acid sequences, Los Alamos National Laboratory, 1995.
5. Wieland U, Pfister H. Molecular diagnosis of persistent human papilloma virus infection. Intervirology. 39:1996;145-157.
6. de Villiers E M. Heterogeneity of the human papillomavirus group. J Virol. 63:1989;4898-4903.
7. Bosch F X, Manos M M, Munoz N, Sherman J, Jansen A M, Peto J, Schiffman M H, Moreno V, Kurman R, Shah K V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 87:1995;796-802.
8. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA. 86:1989;8763-8767.
9. Finlay C A, Hinds P W, Levine A J. The p53 protooncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093.
10. Hollstein M, Rice K, Greenblatt M S, Soussi T, Fuchs R, Sorlie T, Hovig E, Smiyh-Sorensen B, Montesano R, Harris C C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:1994;3551-3555.
11. Werness B A, Levine A J, Howley P M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
12. Scheffner M, Werness B A, Huibregste J M, Levine A J, Howley P M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
13. Scheffner M, Huibregtse J M, Vierstra R D, Howley P M. The HPV-16 E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
14. Crook T, Wrede D, Vousden K H. p53 point mutation in HPV-negative human cervical carcinoma cell lines. Oncogene. 6:1991;873-875.
15. Kurvinen K, Tervahauta A, Syrjanen S, Chang F, Syrjanen K. The state of the p53 gene in human papillomavirus (HPV)-positive and HPV-negative genital precancer lesions and carcinomas as determined by single-strand conformation polymorphism analysis and sequencing. Anticancer Res. 14:1994;177-181.
16. Kessis T D, Slebos R J, Han S M, Shah K, Bosch X F, Munoz N, Hedrick L, Cho K R. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol. 143:1993;1398-1405.
17. Park D J, Wilczynski S P, Paquette R L, Miller C W, Koeffler H P. p53 mutation in HPV-negative cervical carcinoma. Oncogene. 9:1994;205-210.
18. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarz M, Goppinger A, Pfleiderer A. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer. 76:1995;57-66.
19. Tokita H, Tanaka N, Sekimoto K, Ueno T, Okamoto K, Fujimura S. Experimental model for combination chemotherapy with metronidazol using human uterine cervical carcinomas transplanted into nude mice. Cancer Res. 40:1980;4287-4294.
20. Sekiya S, Tanaka N, Takamizawa H. Production of various marker substances in human ovarian cancer cell lines of epithelial origin. Arch Gynecol Obstet. 248:1990;103-110.
21. Pathak S. Chromosome banding techniques. J Reprod Med. 17:1976;25-28.
22. Manos M M, Ting Y, Wright D K, Lewis A J, Broker T R, Wolinsky S M. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell. 7:1989;209-214.
23. Bauer H M, Ting Y, Greer C E, Chambers J C, Tashiro C J, Chimera J, Reingold A, Manos M M. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 265:1991;472-477.
24. Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol. 72:1991;1039-1044.
25. Shirasawa H, Tomita Y, Kubota K, Kasai T, Sekiya S, Takamizawa H, Shimizu B. Detection of human papillomavirus type 16 DNA and evidence for integration into the cell DNA in cervical dysplasia. J Gen Virol. 67:1986;2011-2015.
26. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol. 6:1986;1379-1385.
27. Yee C, Krishnan-Hewlett I, Baker C C, Schlegel R, Howley P M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol. 119:1985;361-366.
28. Matsunaga K, Mashiba H, Gojobori M, Jimi S. Antibody-dependent cell-mediated cytotoxicity of sera from cancer patients against cultured cervical cancer cell lines. Gann. 70:1979;1-7.
29. Matlashewski G J, Tuck S, Pim D, Lamb P, Schneider J, Crawford L V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 7:1987;961-963.
30. Takano H, Harigaya K, Ishii G, Sugaya Y, Soeta S, Nunoyama T, Shirasawa H, Shimizu K, Tokita H, Shimizu B, Mikata A, Sekiya S. Interleukin-6 (IL-6) production in carcinoma of the cervix. Arch Gynecol Obstet. 258:1996;25-33.
31. Bernard H U, Chan S Y, Manos M M, Ong C K, Villa L L, Delius H, Peyton C L, Bauer H M, Wheeler C M. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis. 170:1994;1077-1085.
32. Cho Y, Gorina S, Jeffrey P D, Pavletich N P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
33. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, Vries S D, George T, Fuentes J, Carroll P, Mihatsch M J, Waldman F M. Physical deletion of the p53 gene in bladder cancer: detection by fluorescence in situ hybridization. Am J Pathol. 144:1994;756-766.
34. Kobayashi M, Kawashima A, Mai M, Ooi A. Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dualcolor fluorescence in situ hybridization. Am J Pathol. 149:1996;1575-1584.
35. Higgins G D, Davy M, Roder D, Uzelin D M, Phillips G E, Burrell C J. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet. 338:1991;910-913.
36. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G. Association between poor prognosis in early stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet. 335:1990;1171-1174.